MX2015006096A - Leucocitos como celulas de administracion para imagen y terapia de enfermedad. - Google Patents

Leucocitos como celulas de administracion para imagen y terapia de enfermedad.

Info

Publication number
MX2015006096A
MX2015006096A MX2015006096A MX2015006096A MX2015006096A MX 2015006096 A MX2015006096 A MX 2015006096A MX 2015006096 A MX2015006096 A MX 2015006096A MX 2015006096 A MX2015006096 A MX 2015006096A MX 2015006096 A MX2015006096 A MX 2015006096A
Authority
MX
Mexico
Prior art keywords
leukocytes
imaging
disease therapy
delivery cells
delivery
Prior art date
Application number
MX2015006096A
Other languages
English (en)
Inventor
Deryl L Troyer
Stefan H Bossmann
Hongwang Wang
Matthew T Basel
Tej B Shrestha
Sebastian Wendel
Original Assignee
Deryl L Troyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deryl L Troyer filed Critical Deryl L Troyer
Publication of MX2015006096A publication Critical patent/MX2015006096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos teranósticos en la presente, que son útiles en la diagnosis y/o tratamiento de infección, inflamación y/o cáncer. Los métodos utilizan leucocitos que se presentan en la naturaleza para la terapia fotodinámica e imagen in situ y para la administración de terapias apuntadas a la infección, inflamación y/o cáncer.
MX2015006096A 2012-11-19 2013-11-18 Leucocitos como celulas de administracion para imagen y terapia de enfermedad. MX2015006096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728083P 2012-11-19 2012-11-19
PCT/US2013/070515 WO2014078768A1 (en) 2012-11-19 2013-11-18 Leukocytes as delivery cells for imaging and disease therapy

Publications (1)

Publication Number Publication Date
MX2015006096A true MX2015006096A (es) 2015-12-01

Family

ID=50731749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006096A MX2015006096A (es) 2012-11-19 2013-11-18 Leucocitos como celulas de administracion para imagen y terapia de enfermedad.

Country Status (3)

Country Link
US (1) US20150224211A1 (es)
MX (1) MX2015006096A (es)
WO (1) WO2014078768A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
CN109568269B (zh) * 2018-10-19 2021-12-21 广州医科大学 一种具有诊疗功能外泌体及其制备方法
CN112138157B (zh) * 2020-09-29 2022-02-18 同济大学 一种光学控制的粒细胞生物制剂及其制备与应用
CN114469865B (zh) * 2022-03-17 2023-09-22 中国医学科学院输血研究所 一种与血细胞膜结合的脂质体药物载体及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2318002T3 (es) * 2001-03-30 2009-05-01 Ghc Research Development Corporation Vehiculo de administracion en forma de particulas especifico para monocitos.
IL168184A (en) * 2005-04-21 2011-11-30 Univ Ariel Res & Dev Co Ltd Use of a ligand-photosensitizer conjugate in combination with a chemiluminescent agent in the manufacture of a medicament for photodynamic therapy
WO2012040105A2 (en) * 2010-09-21 2012-03-29 Kansas State University Research Foundation Renilla/gaussia transfected cells as a light source for in-situ photodynamic therapy of cancer

Also Published As

Publication number Publication date
WO2014078768A1 (en) 2014-05-22
US20150224211A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
WO2015009726A3 (en) Medical uses of cd38 agonists
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MY166014A (en) Combination therapy methods for treating proliferative diseases
AU2011328009A8 (en) Compounds and methods for treating pain
EA201400625A1 (ru) Антитела против pd-l1 и их применение
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
MX2015012922A (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
TW201611843A (en) Methods of treatment with arginine deiminase
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
IN2014MN01945A (es)
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
MX2012003287A (es) Uso de la identificacion microambiental de sparc en el tratamiento del cancer.